Updating results

Parenteral nutrition in neonates

Proposed [GID-QS10087] Expected publication date: TBC

Quality standard Proposed

Diverticular disease

Proposed [GID-QS10086] Expected publication date: TBC

Quality standard Proposed

Pancreatitis (including acute pancreatitis)

Proposed [GID-QS10085] Expected publication date: TBC

Quality standard Proposed

Pain management (young people and adults)

Proposed [GID-QS10093] Expected publication date: TBC

Quality standard Proposed

Primary and secondary brain cancers

Proposed [GID-QS10092] Expected publication date: TBC

Quality standard Proposed

Tinnitus

Proposed [GID-QS10091] Expected publication date: TBC

Quality standard Proposed

Hepatitis C

Proposed [GID-QS10126] Expected publication date: TBC

Quality standard Proposed

Water borne infections

Proposed [GID-QS10125] Expected publication date: TBC

Quality standard Proposed

Vulnerable populations: strategies for tackling inequalities

Proposed [GID-QS10124] Expected publication date: TBC

Quality standard Proposed

Transport and health

Proposed [GID-QS10123] Expected publication date: TBC

Quality standard Proposed

Programme management: effective ways to run public health programmes to generate a change in behaviour

Proposed [GID-QS10122] Expected publication date: TBC

Quality standard Proposed

Gambling

Proposed [GID-QS10099] Expected publication date: TBC

Quality standard Proposed

Natural environments

Proposed [GID-QS10119] Expected publication date: TBC

Quality standard Proposed

Heat wave planning

Proposed [GID-QS10116] Expected publication date: TBC

Quality standard Proposed

Mental well-being: life course, settings and subgroups

Proposed [GID-QS10118] Expected publication date: TBC

Quality standard Proposed

Spatial planning

Proposed [GID-QS10112] Expected publication date: TBC

Quality standard Proposed

Road safety

Proposed [GID-QS10111] Expected publication date: TBC

Quality standard Proposed

Non-antibiotic clinical management of infectious diseases

Proposed [GID-QS10120] Expected publication date: TBC

Quality standard Proposed

Prevention of dementia

Proposed [GID-QS10109] Expected publication date: TBC

Quality standard Proposed

Secondary care management of malignant hypertension

Proposed [GID-QS10107] Expected publication date: TBC

Quality standard Proposed

Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

Proposed [GID-QS10106] Expected publication date: TBC

Quality standard Proposed

Gout

Proposed [GID-QS10100] Expected publication date: TBC

Quality standard Proposed

Blood transfusion in neonatology

Proposed [GID-QS10098] Expected publication date: TBC

Quality standard Proposed

Readmission to ICU within 48hrs

Proposed [GID-QS10105] Expected publication date: TBC

Quality standard Proposed

Nutrition in hospital

Proposed [GID-QS10104] Expected publication date: TBC

Quality standard Proposed

Eculizumab for treating relapsing neuromyelitis optica [ID1271]

Proposed [GID-TA10469] Expected publication date: TBC

Technology appraisal guidance Proposed

Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

Proposed [GID-TA10470] Expected publication date: TBC

Technology appraisal guidance Proposed

STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Technology appraisal guidance Proposed

Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

Proposed [GID-TA10199] Expected publication date: TBC

Technology appraisal guidance Proposed

Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Technology appraisal guidance Proposed

Ozanimod for treating relapsing multiple sclerosis [ID1294]

Proposed [GID-TA10299] Expected publication date: TBC

Technology appraisal guidance Proposed

Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Technology appraisal guidance Proposed

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

Proposed [GID-TA10297] Expected publication date: TBC

Technology appraisal guidance Proposed

Adrenal dysfunction

Proposed [GID-QS10038] Expected publication date: TBC

Quality standard Proposed

Acne

Proposed [GID-QS10036] Expected publication date: TBC

Quality standard Proposed

Abdominal aortic aneurysm

Proposed [GID-QS10035] Expected publication date: TBC

Quality standard Proposed

Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]

Proposed [GID-TA10524] Expected publication date: 26 June 2020

Technology appraisal guidance Proposed

Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

Proposed [GID-TA10526] Expected publication date: TBC

Technology appraisal guidance Proposed

Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

Proposed [GID-TA10387] Expected publication date: TBC

Technology appraisal guidance Proposed

Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

Proposed [GID-TA10451] Expected publication date: 10 June 2020

Technology appraisal guidance Proposed

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

Proposed [GID-TA10518] Expected publication date: TBC

Technology appraisal guidance Proposed

Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

Proposed [GID-TA10527] Expected publication date: TBC

Technology appraisal guidance Proposed

Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]

Proposed [GID-TA10520] Expected publication date: TBC

Technology appraisal guidance Proposed

Ranibizumab for treating diabetic retinopathy [ID1592]

Proposed [GID-TA10521] Expected publication date: TBC

Technology appraisal guidance Proposed

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

Proposed [GID-TA10390] Expected publication date: TBC

Technology appraisal guidance Proposed